{"name":"Kamada, Ltd.","slug":"kamada-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KamRAB - HRIG","genericName":"KamRAB - HRIG","slug":"kamrab-hrig","indication":"Post-exposure prophylaxis of rabies in non-vaccinated or incompletely vaccinated individuals","status":"phase_3"}]}],"pipeline":[{"name":"KamRAB - HRIG","genericName":"KamRAB - HRIG","slug":"kamrab-hrig","phase":"phase_3","mechanism":"KamRAB is a human rabies immunoglobulin (HRIG) that provides passive immunity by supplying antibodies against rabies virus.","indications":["Post-exposure prophylaxis of rabies in non-vaccinated or incompletely vaccinated individuals"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRFVzalEteDRNWWE3M3JTWFlacURvX1JQSHBweGJqRXZZUjFzYktRUnlkMmFuNzMtZDV6M1k1Rm9jV20ydFUwNksybHNGTG81WVlIaWRtMF90TlpsTURvOXE3YXRKVzE2bFdVcEJIdS02NWdFeWJRQkV5VUg4N0VRR3ZKZFBrYUV5b0xEaGstNVFwUkR5U0Flb3dFcS0?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Trends in Growth, Segment Analysis, and Competitive Approaches Influencing the Albumin Market - openPR.com","headline":"Trends in Growth, Segment Analysis, and Competitive Approaches Influencing the Albumin Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOQkNfSmlLelM3b2tXbDNnd1lkRU9GeGhBVVA2N0tCNkFGN0dfMzVTckNuSnhaV0tpMEZVelFiaEQ1dUcxZGxFS3ZJeEI1MFBYM2JjOFIxT00wNHhxdUNSQUJVUTA3bzNOelJlbmJoS3VQZG5sOW9veF9MbDZwaUw3M2xZdUpRVTZSbkxWNmllWWY3aEIxeXo3Y1dfRTV6RmFWLTFNS0VMRjFuVDFPVXdfcmJ2TFB4YUoxeV9PdTFhLWxUMFEyYWVfQjg0ajU4XzBMbGQzc1pGem1HRHhLeXhta2h6TG1LV0c3blE?oc=5","date":"2026-03-26","type":"regulatory","source":"GlobeNewswire","summary":"Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas - GlobeNewswire","headline":"Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQY0h4RkdiWDh6aDZrUy1fcWlDdk1lVmNpdFRKWFNlSDVXcDhiaE0xNmR0TTBwNkEzbjJnWjBOcEI5Vlk5eENKdTVVSUF0UEZkUmt6NWN0LU9sTFhGREc5QnJ0X0VGRzZ6TmtqOXpKblltTnVWYlVaWEVfNDhZYVNiaGVBNy1lNHVIQ0VPcmNwamVzNjl5eHFzUUhyUDhCV1JLeldRWHVLaFB2OUdBTTJnQ0FhYlJuR3M?oc=5","date":"2026-03-11","type":"pipeline","source":"Stock Titan","summary":"Biotech Kamada starts paying cash dividends, pledges 50% of net income - Stock Titan","headline":"Biotech Kamada starts paying cash dividends, pledges 50% of net income","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQUmpNalVuNm5qMWdadHhxUTdlM3FTZklIYU02enJNMENlbjRHTVV0dVRDNHlkS0FsaDFmVmtTZHhXYnMwOVZNUUVsWDhaZlFDWEs4SjQzdnhfMTlnb0Rsb3hvdEJXRXp3RndXUTVTT1lfMlZDNlhZOHZNQmdxSjFobTJFODk1OEI2d1o4?oc=5","date":"2026-03-04","type":"earnings","source":"Yahoo Finance","summary":"Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 - Yahoo Finance","headline":"Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQVEhKU1BBMGwwaDlzQlNnOVI0S3lZTDhqSDhvZEMyWHpQU3Nieng5ajBBTG9sZUM0SEh2UVpOMWEwa25CdjhFSHlEU1k0VGd1TU0wSU5mclZoNldQR213MTJQN0NRdW56ZDkwcUxwVzFVQWtjQlN0Zm1BUEwwZ2ZXYmd6dVNBUTZFRk5YY1JXWDNkR3dWY1QtWVFvcjU2YS1sLWJ3SW16UXBfUGZpWUxWa214aWR1NXEwMVBBRVRoajFjVnFBZ2ZVcGUzcHk?oc=5","date":"2026-01-22","type":"pipeline","source":"AD HOC NEWS","summary":"Kamada Ltd: Biopharma under Pressure as KMDA Stock Tests Investor Patience - AD HOC NEWS","headline":"Kamada Ltd: Biopharma under Pressure as KMDA Stock Tests Investor Patience","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-08","type":"trial","source":"GlobeNewswire","summary":"Kamada Announces Discontinuation of its Phase 3 Inhaled AAT - GlobeNewswire","headline":"Kamada Announces Discontinuation of its Phase 3 Inhaled AAT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxNcG1IcVpOVExYUG1XSVNJaGFNNzJVcXFoWVJKMDFTaHBJNi1DX2dxOE80azlSUHdtRHIzNTZ6dXhEUXFDcl9HVGYxRWZpekVTY1MtVXRqV2lkb2l5bEFWZlQzbE5lT2pSY3BDaU1nQkllOEZ1Snk3Q3lnb1dPRzdPWkR6ZFVKLW1YUWZsZHgxS2ZMa0JybXBmcXlOdXRfTThuX0JwMkhBVGhhTU1lNEVwODBjM1pQQjRKb2NBeXl4V1pVZEI4NW1URVNlajQ5ZVZKcWtEb3o1eVgtdkh3TXhSTFhScEpZaGlUdUhtR09zU2JFY0Q3VllKa00ySXRqMVV4WlJEN0tQbmtKalp6U2dCaEpxblhJYzJTVDEwTXU0OXNWNWxQbXJ5Wk5XRk9jY3FqY3EyaElUdUI?oc=5","date":"2025-11-06","type":"patent","source":"Finansavisen","summary":"Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA - Finansavisen","headline":"Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"regulatory","source":"BioSpace","summary":"Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar ","headline":"Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorizat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNUW42bVZTM2RJejFNX3kxQ1pJTFdDVjY2eG4zWFljc1R5OVlBQWc0R01ScTlmNlk4dHFVWXBGTEtMT0RfRjZxRmktOW9FeWszcU1oQVFQTFdtS2RJb3BYWWx4S0lFdzcxb1NfRjVnRG15ZWVrRmtnNEV2OXh6ejRFdW9TWkpEc0lyUDBzRWF2VzRueDhs?oc=5","date":"2025-10-06","type":"deal","source":"seekingalpha.com","summary":"My Top 5 Biotech Stocks Big Pharma Could Buy Next - seekingalpha.com","headline":"My Top 5 Biotech Stocks Big Pharma Could Buy Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQZHU4QVFLTnZyS1hrNGl3Q2dGZHFoMGE2bFoweGx3Xy1pS1B4VlJNcXQ4b3hsc0dvVVJjZXJ4TkpGTGlxNmRUbm85Z2dNejNvaU1uZ2p2R2FTZHZjNWZuQ1JweExleno3TkJGTFNDeWxLUjd3NjBkdVZFLXE5RlVscFdQVjVuaU5QWmc?oc=5","date":"2024-08-28","type":"deal","source":"Yahoo Finance","summary":"Kamada Ltd. (KMDA): A Cheap Pharmaceutical Stock to Buy According to Short Sellers - Yahoo Finance","headline":"Kamada Ltd. (KMDA): A Cheap Pharmaceutical Stock to Buy According to Short Sellers","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-18","type":"pipeline","source":"prnewswire.com","summary":"Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Kamada Pharmaceuticals, Arrowhead Pharmaceuticals, Takeda, Mereo BioPharma, AstraZ","headline":"Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key Companies - Ka","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNWTZ5WDJPY1NvRWRQX2JoX2ZWSkhhR0FpcnIwRG1Jam96VGRVRmMzOENkWTVsaXVXb0hVbUVERHdEOTI2NXQ2QWdVdDE3NjUtMG5EaWc1bWtNWUpxTFBzRVZpMk9yN0E1R1ViQjRvOWk5YUlsVUxxSzhrbjI3b19yYU1Db01rYUpHNUo1djc1U2pyTjVhTnB5U3Mtc2JheU9OODJKa3I3amF1d3dSdWpUX1ZpandWa3N5MzBxN0VheWNjY0Z3aENXREFGUUpUdWlYSktqQ2FDNA?oc=5","date":"2023-12-26","type":"pipeline","source":"respiratory-therapy.com","summary":"Kamada Seeks EU Clearance for Inhaled Alpha-1 Therapy - respiratory-therapy.com","headline":"Kamada Seeks EU Clearance for Inhaled Alpha-1 Therapy - respiratory","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}